Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity

被引：11

作者：

Garassino, Marina Chiara ^{[1
]}

Torri, Valter ^{[2
]}

Colombo, Mario Paolo ^{[3
]}

Sica, Antonio ^{[4
,5
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Thorac Oncol Unit, I-20133 Milan, Italy

[2] IRCCS Mario Negri Inst Pharmacol Res, Oncol Dept, Methodol Clin Res Lab, Milan, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, Milan, Italy

[4] Univ Piemonte Orientale, Dept Pharmaceut Sci, Novara, Italy

[5] Humanitas Clin & Res Ctr, Dept Inflammat & Immunol, Milan, Italy

来源：

CANCER RESEARCH | 2018年 / 78卷 / 20期

关键词：

POLARIZATION;

D O I：

10.1158/0008-5472.CAN-18-2245

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite the fact that reactivation of specific antitumor immunity through inhibition of immune checkpoints represents a formidable therapeutic weapon against cancer, many patients are poorly reactive to this treatment. To overcome this limitation, efforts are being made to characterize the immunostimulatory properties of chemotherapeutic agents and how they can be best combined with immune checkpoint inhibitors. The work by Wanderley and colleagues indicates that the TLR4 agonist taxol can restore the anticancer activity of tumor-associated macrophages and improve the clinical efficacy of immune checkpoint inhibitors. (C) 2018 AACR. See related article by Wanderley et al., p. 5891

引用

页码：5729 / 5730

页数：2

共 10 条

[1] Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-γ:: a molecular basis for priming and synergism with bacterial lipopolysaccharide [J].

Bosisio, D ;

Polentarutti, N ;

Sironi, M ;

Bernasconi, S ;

Miyake, K ;

Webb, GR ;

Martin, MU ;

Mantovani, A ;

Muzio, M .

BLOOD, 2002, 99 (09) :3427-3431

[2] Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents [J].

Galluzzi, Lorenzo ;

Buque, Aitziber ;

Kepp, Oliver ;

Zitvogel, Laurence ;

Kroemer, Guido .

CANCER CELL, 2015, 28 (06) :690-714

[3] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[4] Mouse toll-like receptor 4•MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol [J].

Kawasaki, K ;

Akashi, S ;

Shimazu, R ;

Yoshida, T ;

Miyake, K ;

Nishijima, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (04) :2251-2254

[5]

Novosiadly R, 2018, P AM ASS CANC RES AN

[6] Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB [J].

Porta, Chiara ;

Rimoldi, Monica ;

Raes, Geert ;

Brys, Lea ;

Ghezzi, Pietro ;

Di Liberto, Diana ;

Dieli, Francesco ;

Ghisletti, Serena ;

Natoli, Gioacchino ;

De Baetselier, Patrick ;

Mantovani, Alberto ;

Sica, Antonio .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (35) :14978-14983

[7] Macrophage plasticity and polarization: in vivo veritas [J].

Sica, Antonio ;

Mantovani, Alberto .

JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (03) :787-795

[8] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

[9] TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells [J].

Sun, Nian-Kang ;

Huang, Shang-Lang ;

Chang, Ting-Chang ;

Chao, Chuck C. -K. .

JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (03) :2489-2501

[10] Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner [J].

Wanderley, Carlos W. ;

Colon, David F. ;

Luiz, Joao Paulo M. ;

Oliveira, Francisco F. ;

Viacava, Paula R. ;

Leite, Caio A. ;

Pereira, Janaina A. ;

Silva, Camila M. ;

Silva, Cassia R. ;

Silva, Rangel L. ;

Speck-Hernandez, Cesar A. ;

Mota, Jose M. ;

Alves-Filho, Jose C. ;

Lima-Junior, Roberto C. ;

Cunha, Thiago M. ;

Cunha, Fernando Q. .

CANCER RESEARCH, 2018, 78 (20) :5891-5900

← 1 →